GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Suven Pharmaceuticals Ltd (BOM:543064) » Definitions » Owner Earnings per Share (TTM)

Suven Pharmaceuticals (BOM:543064) Owner Earnings per Share (TTM) : 11.74 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Suven Pharmaceuticals Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Suven Pharmaceuticals's Owner Earnings per Share (TTM) ended in Mar. 2024 was ₹11.74. It's Price-to-Owner-Earnings ratio for today is 55.09.


The historical rank and industry rank for Suven Pharmaceuticals's Owner Earnings per Share (TTM) or its related term are showing as below:

BOM:543064' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 32.74   Med: 34.16   Max: 57.2
Current: 52.71


During the past 6 years, the highest Price-to-Owner-Earnings ratio of Suven Pharmaceuticals was 57.20. The lowest was 32.74. And the median was 34.16.


BOM:543064's Price-to-Owner-Earnings is ranked worse than
79.91% of 423 companies
in the Drug Manufacturers industry
Industry Median: 25.31 vs BOM:543064: 52.71

Suven Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was ₹2.10. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹11.81. It's PE Ratio ratio for today is 54.76.

Suven Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2024 was ₹2.10. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was ₹11.81. It's PE Ratio without NRI ratio for today is 54.76.


Suven Pharmaceuticals Owner Earnings per Share (TTM) Historical Data

The historical data trend for Suven Pharmaceuticals's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suven Pharmaceuticals Owner Earnings per Share (TTM) Chart

Suven Pharmaceuticals Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial - - - 14.21 11.74

Suven Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.21 - - - 11.74

Competitive Comparison of Suven Pharmaceuticals's Owner Earnings per Share (TTM)

For the Drug Manufacturers - Specialty & Generic subindustry, Suven Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Suven Pharmaceuticals's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Suven Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Suven Pharmaceuticals's Price-to-Owner-Earnings falls into.



Suven Pharmaceuticals Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Suven Pharmaceuticals's Owner Earnings per Share (TTM) Calculation:

Last Year Average of Last 5 Years
Net Income 3,003
Depreciation, Depletion and Amortization 518
Change In Deferred Tax 0
5Y Average of Maintenance Capital Expenditure 1,009
Change In Working Capital 474
Shares Outstanding (Diluted Average) 254

1. Start with "Net Income" from income statement. Suven Pharmaceuticals's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was ₹3,003 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Suven Pharmaceuticals's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Mar. 2024 was ₹518 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Suven Pharmaceuticals's Change In Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2024 was ₹0 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = ₹1,009 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Suven Pharmaceuticals's 5-Year Average Maintenance Capital Expenditure = ₹1,009 Mil

5. "Change In Working Capital" is from cashflow statement. Suven Pharmaceuticals's Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 was ₹474 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Suven Pharmaceuticals's Shares Outstanding (Diluted Average) for the months ended in Mar. 2024 was 254.475 Mil.

Suven Pharmaceuticals's Onwer Earnings Per Share for Mar. 2024 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( 3002.806 +518.059+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-1008.8112+474.118)/254.475
=11.74

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=646.75/11.74
=55.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Suven Pharmaceuticals Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Suven Pharmaceuticals's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Suven Pharmaceuticals (BOM:543064) Business Description

Traded in Other Exchanges
Address
3rd Floor, Road No. 5, Avenue 7, Banjara Hills, No. 8-2-334, SDE Serene Chambers, Hyderabad, TG, IND, 500034
Suven Pharmaceuticals Ltd is engaged in the development and manufacturing of Intermediates, Active Pharmaceutical Ingredients (API), specialty chemicals and formulated drugs under Contract Research and Manufacturing Services (CRAMS) for global pharmaceutical, biotechnology and chemical companies. The company has single operating segment that is Pharmaceuticals Manufacturing & Services and its geographical segments include India; the USA; Europe and the Rest of the World. The company derives a majority of revenue from the Europe segment.

Suven Pharmaceuticals (BOM:543064) Headlines

No Headlines